BNP Paribas Financial Markets’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.13M | Sell |
371,176
-63,902
| -15% | -$191K | ﹤0.01% | 3235 |
|
|
2026
Q1 | $1.34M | Buy |
435,078
+257,773
| +145% | +$1.09M | ﹤0.01% | 2934 |
|
|
2025
Q4 | $640K | Buy |
177,305
+102,772
| +138% | +$448K | ﹤0.01% | 3427 |
|
|
2025
Q3 | $281K | Buy |
74,533
+64,438
| +638% | +$249K | ﹤0.01% | 3850 |
|
|
2025
Q2 | $39.1K | Buy |
10,095
+5,253
| +108% | +$28.4K | ﹤0.01% | 4349 |
|
|
2025
Q1 | $24.2K | Sell |
4,842
-3,314
| -41% | -$21K | ﹤0.01% | 4484 |
|
|
2024
Q4 | $58.8K | Sell |
8,156
-33,984
| -81% | -$260K | ﹤0.01% | 4356 |
|
|
2024
Q3 | $259K | Buy |
42,140
+32,072
| +319% | +$217K | ﹤0.01% | 3153 |
|
|
2024
Q2 | $67K | Sell |
10,068
-22,357
| -69% | -$165K | ﹤0.01% | 3386 |
|
|
2024
Q1 | $330K | Buy |
32,425
+19,661
| +154% | +$200K | ﹤0.01% | 3068 |
|
|
2023
Q4 | $144K | Buy |
12,764
+5,987
| +88% | +$25K | ﹤0.01% | 3313 |
|
|
2023
Q3 | $17.6K | Sell |
6,777
-4,833
| -42% | -$13.9K | ﹤0.01% | 3574 |
|
|
2023
Q2 | $41K | Sell |
11,610
-327,566
| -97% | -$1.47M | ﹤0.01% | 3517 |
|
|
2023
Q1 | $1.43M | Buy |
339,176
+234,091
| +223% | +$2.78M | ﹤0.01% | 2074 |
|
|
2022
Q4 | $1.73M | Buy |
105,085
+22,746
| +28% | +$255K | ﹤0.01% | 1842 |
|
|
2022
Q3 | $1.05M | Buy |
82,339
+81,194
| +7,091% | +$1.2M | ﹤0.01% | 2452 |
|
|
2022
Q2 | $13.4K | Sell |
1,145
-7,691
| -87% | -$47.4K | ﹤0.01% | 3725 |
|
|
2022
Q1 | $53.8K | Sell |
8,836
-50,751
| -85% | -$374K | ﹤0.01% | 3545 |
|
|
2021
Q4 | $546K | Buy |
59,587
+50,257
| +539% | +$534K | ﹤0.01% | 2968 |
|
|
2021
Q3 | $106K | Buy |
9,330
+5,909
| +173% | +$71.9K | ﹤0.01% | 3253 |
|
|
2021
Q2 | $33.7K | Sell |
3,421
-35,541
| -91% | -$486K | ﹤0.01% | 3395 |
|
|
2021
Q1 | $551K | Buy |
+38,962
| New | +$630K | ﹤0.01% | 2513 |
|
|
2019
Q4 | – | Sell |
-1
| Closed | -$2 | – | 4423 |
|
|
2019
Q3 | $2 | Hold |
1
| – | – | ﹤0.01% | 4502 |
|
|
2019
Q2 | $2 | Hold |
1
| – | – | ﹤0.01% | 4527 |
|
|
2019
Q1 | $3 | Hold |
1
| – | – | ﹤0.01% | 4268 |
|
|
2018
Q4 | $2 | Hold |
1
| – | – | ﹤0.01% | 4311 |
|
|
2018
Q3 | $4 | Hold |
1
| – | – | ﹤0.01% | 4426 |
|
|
2018
Q2 | $10 | Hold |
1
| – | – | ﹤0.01% | 4392 |
|
|
2018
Q1 | $26 | Hold |
1
| – | – | ﹤0.01% | 4174 |
|
|
2017
Q4 | $44 | Hold |
1
| – | – | ﹤0.01% | 4162 |
|
|
2017
Q3 | $51 | Hold |
1
| – | – | ﹤0.01% | 4172 |
|
|
2017
Q2 | $70 | Buy |
+1
| New | +$166 | ﹤0.01% | 4183 |
|
|
2017
Q1 | – | Sell |
-10
| Closed | -$5.35K | – | 4051 |
|
|
2016
Q4 | $9.83K | Sell |
10
-5
| -33% | -$4.48K | ﹤0.01% | 3465 |
|
|
2016
Q3 | $13.5K | Buy |
15
+7
| +88% | +$5.49K | ﹤0.01% | 3088 |
|
|
2016
Q2 | $6.01K | Buy |
+8
| New | +$5.47K | ﹤0.01% | 3181 |
|
|
2014
Q3 | – | Sell |
-3
| Closed | -$1.3K | – | 4088 |
|
|
2014
Q2 | $1.3K | Hold |
3
| – | – | ﹤0.01% | 3335 |
|
|
2014
Q1 | $1.27K | Hold |
3
| – | – | ﹤0.01% | 2790 |
|
|
2013
Q4 | $1.72K | Buy |
+3
| New | +$1.79K | ﹤0.01% | 3725 |
|
Other funds holding ALT
DTC
TCM
RCM
BNP Paribas Financial Markets's ALT Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Altimmune (ALT) stake by 15% in Q2 2026, selling an estimated $191K and leaving 371,176 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3235.
BNP Paribas Financial Markets first reported a position in ALT in Q4 2013 and has held it in 38 quarters since. The position peaked at $1.73M in Q4 2022. 207 funds tracked by Wall St. Rank hold ALT as of Q2 2026.
- BNP Paribas Financial Markets held 371,176 shares of Altimmune worth $1.13M as of Q2 2026.
- BNP Paribas Financial Markets sold 63,902 Altimmune shares in Q2 2026, an estimated $191K.
- Altimmune made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3235 holding.
- BNP Paribas Financial Markets first reported a position in Altimmune in Q4 2013 and has held it in 38 quarters since.
- BNP Paribas Financial Markets's Altimmune position peaked at $1.73M in Q4 2022.
- 207 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.